{"id":981546,"date":"2026-07-14T20:22:05","date_gmt":"2026-07-15T00:22:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/"},"modified":"2026-07-14T20:22:05","modified_gmt":"2026-07-15T00:22:05","slug":"glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/","title":{"rendered":"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform"},"content":{"rendered":"

\nTransaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and L\u014dkahi Therapeutics ai\u00b2-driven asset sourcing, development, and advancement platform
\n<\/h2>\n
\n

RUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with L\u014dkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets.<\/p>\n

The transaction is structured such that L\u014dkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging Glucotrack\u2019s public market platform to support long-term growth and access to capital. The combined organization integrates L\u014dkahi Therapeutics\u2019 dual-engine model – its late-stage clinical development program and ai\u00b2-driven asset sourcing and advancement platform – with Glucotrack\u2019s existing technology infrastructure to create a scalable, repeatable framework for value creation.<\/p>\n

In connection with the closing, L\u014dkahi Therapeutics securityholders received a combination of Glucotrack common stock and convertible preferred stock. Upon receipt of required stockholder approvals and satisfaction of applicable Nasdaq listing requirements, the preferred stock is expected to convert into common equity, resulting in L\u014dkahi Therapeutics securityholders holding approximately 90% of the combined company on a fully diluted basis, subject to transaction-related financing and customary adjustments.<\/p>\n

The transaction is supported by a planned private placement financing designed to strengthen the combined company\u2019s capital position and support near-term execution. A designated portion of the proceeds is expected to be allocated to support the continued development and operation of Glucotrack\u2019s legacy continuous blood glucose monitoring (CBGM) technology within a dedicated subsidiary structure.<\/p>\n

Glucotrack\u2019s CBGM business will operate as a wholly owned subsidiary of the combined company, with its operations, assets, and capital structure maintained separately to enable focused execution and strategic flexibility.<\/p>\n

Erik Emerson has been appointed Chief Executive Officer of the combined company, providing unified leadership across the organization. Paul Goode will serve as Chief Technical Officer of the combined company and Chief Executive Officer of the CBGM subsidiary.<\/p>\n

\u201cThis transaction establishes a capital-efficient, publicly listed platform designed to systematically identify, acquire, and advance differentiated healthcare assets,\u201d said Erik Emerson, Chief Executive Officer. \u201cBy combining public market access with L\u014dkahi Therapeutics\u2019 ai\u00b2 platform and disciplined operating model, we are positioned to expand our pipeline, strengthen our capital structure, and pursue a broader set of strategic opportunities.\u201d<\/p>\n

Paul Goode, Chief Technical Officer, added: \u201cThis combination enables the continued advancement of Glucotrack\u2019s core technology within a focused operating structure while participating in a broader platform designed for scalable growth. We believe this integrated approach supports disciplined execution across both operating priorities.\u201d<\/p>\n

\n About L\u014dkahi Therapeutics<\/strong>\n <\/p>\n

L\u014dkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai\u00b2 platform and ai\u00b2 Futures Lab execution model, L\u014dkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, visit www.lokahithera.com<\/a>.<\/p>\n

\n About Glucotrack, Inc.<\/strong>\n <\/p>\n

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information, please visit www.glucotrack.com<\/a>.<\/p>\n

\n Forward-Looking Statements <\/strong>\n <\/p>\n

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan,” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to merger integration; risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.<\/p>\n

\n Media Contacts:<\/strong>\n <\/p>\n

\n Glucotrack<\/strong>\n <\/p>\n

GlucotrackPR@icrinc.com<\/p>\n

\n L\u014dkahi Therapeutics<\/strong>\n <\/p>\n

brian@lokahithera.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and L\u014dkahi Therapeutics ai\u00b2-driven asset sourcing, development, and advancement platform RUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with L\u014dkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets. The transaction is structured such that L\u014dkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging Glucotrack\u2019s public market platform to support long-term growth and access to capital. The combined organization integrates L\u014dkahi Therapeutics\u2019 dual-engine model – its late-stage clinical development program and ai\u00b2-driven asset sourcing and advancement … <\/p>\n

Continue reading “Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-981546","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGlucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and L\u014dkahi Therapeutics ai\u00b2-driven asset sourcing, development, and advancement platform RUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with L\u014dkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets. The transaction is structured such that L\u014dkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging Glucotrack\u2019s public market platform to support long-term growth and access to capital. The combined organization integrates L\u014dkahi Therapeutics\u2019 dual-engine model – its late-stage clinical development program and ai\u00b2-driven asset sourcing and advancement … Continue reading "Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T00:22:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjI5NyM3NzAwNjE2IzIyOTc2Nzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform\",\"datePublished\":\"2026-07-15T00:22:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/\"},\"wordCount\":923,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjI5NyM3NzAwNjE2IzIyOTc2Nzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/\",\"name\":\"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjI5NyM3NzAwNjE2IzIyOTc2Nzk=\",\"datePublished\":\"2026-07-15T00:22:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjI5NyM3NzAwNjE2IzIyOTc2Nzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MjI5NyM3NzAwNjE2IzIyOTc2Nzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/","og_locale":"en_US","og_type":"article","og_title":"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform - Market Newsdesk","og_description":"Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and L\u014dkahi Therapeutics ai\u00b2-driven asset sourcing, development, and advancement platform RUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with L\u014dkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets. The transaction is structured such that L\u014dkahi Therapeutics becomes the operating and controlling business of the combined company, leveraging Glucotrack\u2019s public market platform to support long-term growth and access to capital. The combined organization integrates L\u014dkahi Therapeutics\u2019 dual-engine model – its late-stage clinical development program and ai\u00b2-driven asset sourcing and advancement … Continue reading \"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-15T00:22:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjI5NyM3NzAwNjE2IzIyOTc2Nzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform","datePublished":"2026-07-15T00:22:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/"},"wordCount":923,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjI5NyM3NzAwNjE2IzIyOTc2Nzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/","name":"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjI5NyM3NzAwNjE2IzIyOTc2Nzk=","datePublished":"2026-07-15T00:22:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjI5NyM3NzAwNjE2IzIyOTc2Nzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MjI5NyM3NzAwNjE2IzIyOTc2Nzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-and-lokahi-therapeutics-complete-strategic-business-combination-establishing-lokahi-controlled-public-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Glucotrack and L\u014dkahi Therapeutics Complete Strategic Business Combination, Establishing L\u014dkahi-Controlled Public Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=981546"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/981546\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=981546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=981546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=981546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}